Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Blood Flow Speed; Coronary Flow Velocity

Treatments: Drug: AZD6140; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01226602

D5130C00067

2010-021820-91 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.

Enrollment: 39 patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Suitable for ECG recording of CBFV and have no adverse reaction to adenosine challenge
• Have a body mass index between 18 and 30 kg/m2

Exclusion criteria

• History of clinically significant disease or disorder.
• Abnormal vital signs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

39 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder

Treatment:

Drug: AZD6140

2

Placebo Comparator group

Description:

Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder

Treatment:

Drug: Placebo